MOR209 Morphosys - Google News

Aptevo lands $74.5M sale, regains rights to prostate cancer candidate - BioWorld Online

almost 8 years ago

Aptevo lands $74.5M sale, regains rights to prostate cancer candidate  BioWorld Online

With New Cash Aptevo Goes It Alone on Prostate Drug, Shares Up - Biotech Movers - TheStreet.com

almost 8 years ago

BRIEF-Aptevo Therapeutics and MorphoSys ends joint agreement to develop and commercialize MOR209/ES414 - Reuters

almost 8 years ago

Aptevo Therapeutics and MorphoSys End Joint Development and - GlobeNewswire

almost 8 years ago

BRIEF-Aptevo Therapeutics and MorphoSys ends joint agreement to develop and commercialize MOR209/ES414 - Reuters

almost 8 years ago

BRIEF-Aptevo Therapeutics and MorphoSys ends joint agreement to develop and commercialize MOR209/ES414 - Reuters

almost 8 years ago

BRIEF-Aptevo Therapeutics' unit, CMC ICOS Biologics enter non-exclusive amended and restated commercial supply agreement - Reuters

about 8 years ago

Aptevo Therapeutics Amends Collaboration Agreement with - GlobeNewswire

over 8 years ago

BRIEF-Aptevo Therapeutics amends collaboration agreement with Morphosys AG for Novel Immunotherapeutic - Reuters UK

over 8 years ago

Emergent BioSolutions Is Oversold - Forbes

about 9 years ago

MorphoSys, immatics Launch Immuno-Oncology Alliance - Genetic Engineering & Biotechnology News

almost 10 years ago

Emergent BioSolutions Announces Plan to Implement Tax-Free Spin-Off of Biosciences Business Into a Separate - GlobeNewswire

almost 10 years ago